JP6311025B2 - 痛症を治療又は緩和するためのスルファメート誘導体化合物 - Google Patents

痛症を治療又は緩和するためのスルファメート誘導体化合物 Download PDF

Info

Publication number
JP6311025B2
JP6311025B2 JP2016538526A JP2016538526A JP6311025B2 JP 6311025 B2 JP6311025 B2 JP 6311025B2 JP 2016538526 A JP2016538526 A JP 2016538526A JP 2016538526 A JP2016538526 A JP 2016538526A JP 6311025 B2 JP6311025 B2 JP 6311025B2
Authority
JP
Japan
Prior art keywords
benzo
dioxin
dimethyl
chloro
methylsulfamate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016538526A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509582A (ja
JP2017509582A5 (enExample
Inventor
ムン チェ、ヨン
ムン チェ、ヨン
Original Assignee
バイオ−ファーム ソリューションズ カンパニー リミテッド
バイオ−ファーム ソリューションズ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオ−ファーム ソリューションズ カンパニー リミテッド, バイオ−ファーム ソリューションズ カンパニー リミテッド filed Critical バイオ−ファーム ソリューションズ カンパニー リミテッド
Publication of JP2017509582A publication Critical patent/JP2017509582A/ja
Publication of JP2017509582A5 publication Critical patent/JP2017509582A5/ja
Application granted granted Critical
Publication of JP6311025B2 publication Critical patent/JP6311025B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B55/00—Racemisation; Complete or partial inversion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2016538526A 2013-12-12 2014-12-12 痛症を治療又は緩和するためのスルファメート誘導体化合物 Active JP6311025B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915042P 2013-12-12 2013-12-12
US61/915,042 2013-12-12
PCT/KR2014/012260 WO2015088272A1 (en) 2013-12-12 2014-12-12 Sulfamate derivative compounds for use in treating or alleviating pain

Publications (3)

Publication Number Publication Date
JP2017509582A JP2017509582A (ja) 2017-04-06
JP2017509582A5 JP2017509582A5 (enExample) 2018-03-29
JP6311025B2 true JP6311025B2 (ja) 2018-04-11

Family

ID=53371494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016538526A Active JP6311025B2 (ja) 2013-12-12 2014-12-12 痛症を治療又は緩和するためのスルファメート誘導体化合物

Country Status (7)

Country Link
US (1) US10081615B2 (enExample)
EP (1) EP3079687B1 (enExample)
JP (1) JP6311025B2 (enExample)
KR (1) KR101758583B1 (enExample)
CN (1) CN105979942B (enExample)
ES (1) ES2663804T3 (enExample)
WO (1) WO2015088272A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2704928T3 (es) * 2013-12-12 2019-03-20 Bio Pharm Solutions Co Ltd Compuestos derivados de sulfamato para su uso en el tratamiento o alivio del dolor
KR102121680B1 (ko) * 2016-02-29 2020-06-10 (주)바이오팜솔루션즈 설파메이트 유도체 화합물, 이의 제조 방법 및 용도
CN114350340B (zh) * 2022-01-13 2023-01-17 陕西科技大学 一种压裂用增渗剂及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582916A (en) 1983-09-26 1986-04-15 Mcneilab, Inc. Chlorosulfate and azidosulfate esters of tetrahydro-2H-pyran-2-yl-methanol
US4591601A (en) * 1985-04-12 1986-05-27 Mcneilab, Inc. Anticonvulsant dioxolane methane sulfamates
ATE63912T1 (de) * 1987-02-05 1991-06-15 Caber Farmaceutici 4-oxo-1,3-benzodioxan-derivat.
US4792569A (en) 1987-08-27 1988-12-20 Mcneilab, Inc. Anticonvulsant phenethyl sulfamates
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200823196A (en) 2006-11-01 2008-06-01 Astrazeneca Ab New use
MX2010011498A (es) * 2008-04-29 2010-11-12 Nsab Af Neurosearch Sweden Ab Moduladores de neurotransmision de dopamina.
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CA2817290A1 (en) 2010-11-11 2012-05-18 Josef Penninger Compounds and methods for treating pain
EP2861571B1 (en) 2012-06-15 2017-05-03 Bio-Pharm Solutions Co., Ltd. Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same

Also Published As

Publication number Publication date
EP3079687A4 (en) 2017-04-26
JP2017509582A (ja) 2017-04-06
CN105979942B (zh) 2018-12-07
WO2015088272A1 (en) 2015-06-18
WO2015088272A9 (en) 2015-10-01
EP3079687A1 (en) 2016-10-19
KR101758583B1 (ko) 2017-07-14
EP3079687B1 (en) 2018-02-28
ES2663804T3 (es) 2018-04-17
KR20160065984A (ko) 2016-06-09
CN105979942A (zh) 2016-09-28
US10081615B2 (en) 2018-09-25
US20160311792A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
JP6089045B2 (ja) 痛みの緩和または治療に使用するためのフェニルカルバメート化合物
KR20120022801A (ko) 카르복실산 화합물
KR101821646B1 (ko) 암을 치료하기 위한 화합물 및 조성물
JP6311025B2 (ja) 痛症を治療又は緩和するためのスルファメート誘導体化合物
JP6220975B2 (ja) 痛症を治療又は緩和するためのスルファメート誘導体化合物。｛ｓｕｌｆａｍａｔｅ ｄｅｒｉｖａｔｉｖｅ ｃｏｍｐｏｕｎｄｓ ｆｏｒ ｕｓｅ ｉｎ ｔｒｅａｔｉｎｇ ｏｒ ａｌｌｅｖｉａｔｉｎｇ ｐａｉｎ｝
WO2015032328A1 (zh) 茚满衍生物及其制备方法和在医药上的应用
EP2687531A1 (en) Tetrahydrocarboline derivative
JP2025164962A (ja) ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体
JP2017530180A (ja) 骨粗しょう症の予防及び治療用の置換芳香族化合物ならびに医薬組成物
US9150537B2 (en) Bicyclic compound and use thereof for medical purposes
WO2016088834A1 (ja) ジヒドロナフタレン誘導体
CN102040517A (zh) 白藜芦醇衍生物及其医药用途
CN108026084A (zh) 治疗化合物及其使用方法
JP2023552292A (ja) βアドレナリンアゴニスト及びその使用方法
RU2712624C2 (ru) Композиции для лечения заболевания почек и/или печени
CN104003913B (zh) E-3,4-二羟苯乙烯基磺酰胺和磺酸酯类化合物的制备方法及其作为神经保护剂的应用
WO2011075935A1 (zh) 二苯基乙烯类衍生物及其用途
KR20200007804A (ko) Trpv1 조절제 화합물
US20030092695A1 (en) Metal salts of 3-methyl-chromane or thiochromane derivatives
WO2020151621A1 (zh) 化合物、其制备方法及医药用途
JPWO2004103946A1 (ja) カルボン酸化合物及びこれを含有する医薬
JP2005514461A (ja) Ｍｍｐ阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170606

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170905

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20171102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171116

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180309

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180319

R150 Certificate of patent or registration of utility model

Ref document number: 6311025

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250